## **DIGEST**

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HB 291 Original

2020 Regular Session

Davis

**Abstract:** Provides that mucopolysaccharidosis type I (MPS I) and glycogen storage disorder type II (Pompe) diseases shall be added to the list of genetic conditions tested by physicians attending newborn children.

<u>Present law</u> provides that a physician attending to the care of a newborn child shall cause the child to be subjected to a list of genetic conditions provided for in <u>present law</u> that have been approved by the La. Dept. of Health. Further provides that the genetic conditions shall be tested upon approval by the newborn child's parents.

<u>Proposed law</u> retains <u>present law</u> and adds that of the genetic conditions approved by <u>present law</u>, MPS I and Pompe diseases shall be genetic conditions approved by the La. Dept. of Health and shall be tested by physicians attending newborn children, upon the approval by the child's parents.

<u>Proposed law</u> supersedes amendments to <u>present law</u>, R.S. 40:1081.2(A)(1), made by §1 of Act No. 507 of the 2016 Regular Session.

Effective Jan. 1, 2021.

(Amends R.S. 40:1081.2(A)(1))